The Experts below are selected from a list of 5988 Experts worldwide ranked by ideXlab platform
Youqing Shen - One of the best experts on this subject based on the ideXlab platform.
-
Progress and perspective of microneedle system for anti-cancer Drug delivery.
Biomaterials, 2020Co-Authors: Hirak K. Patra, Xiangrui Liu, Zhuxian Zhou, Jianbin Tang, Nigel K.h. Slater, Youqing ShenAbstract:Abstract Transdermal Drug delivery exhibited encouraging prospects, especially through superficial Drug Administration routes. However, only a few limited lipophilic Drug molecules could cross the skin barrier, those are with low molecular weight and rational Log P value. Microneedles (MNs) can overcome these limitations to deliver numerous Drugs into the dermal layer by piercing the outermost skin layer of the body. In the case of superficial cancer treatments, Topical Drug Administration faces severely low transfer efficiency, and systemic treatments are always associated with side effects and premature Drug degradation. MN-based systems have achieved excellent technical capabilities and been tested for pre-clinical chemotherapy, photothermal therapy, photodynamic therapy, and immunotherapy. In this review, we will focus on the features, progress, and opportunities of MNs in the anticancer Drug delivery system. Then, we will discuss the strategies and advantages in these works and summarize challenges, perspectives, and translational potential for future applications.
J. Seebeck - One of the best experts on this subject based on the ideXlab platform.
-
Anaphylaxis and toxic epidermal necrolysis or Stevens–Johnson syndrome after nonmucosal Topical Drug application: fact or fiction?
Allergy, 2007Co-Authors: Bernhardt Sachs, Wilma Fischer-barth, Stephan Erdmann, H.f. Merk, J. SeebeckAbstract:Background: Drug-induced anaphylaxis and toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS) represent severe immediate and delayed-type adverse Drug reactions (ADRs), respectively. Occurrence of such reactions after Topical Drug application has only rarely been reported. Hence, we compiled a large number of such cases which we systematically analyzed. Methods: All such cases contained in the ADR database of the competent pharmacovigilance authority in Germany and cases reported in literature were identified, evaluated and analyzed with regard to potential risk factors. Since the application of Drugs to mucous membranes facilitates their entry to the systemic circulation only cases occurring after non-mucosal Topical Drug application were considered. Results: After evaluation 28 anaphylaxis database cases and 48 anaphylaxis literature cases remained for analysis. Application to skin wounds or to skin with impaired barrier function was identified as a risk factor in 10/28 (36%) of the database cases and in 42/48 (88%) of the literature cases. In 9/28 database cases (32%), anaphylaxis was induced by Drugs used for their hyperemizing effect and, in 8/28 cases (29%) by antibiotics or antiseptics. In the literature cases, anaphylaxis was induced by antibiotics or antiseptics in 35/48 cases (73%). Only one SJS database case and one TEN literature case remained after case evaluation. Conclusion: Anaphylaxis does occur after non-mucosal Topical Drug Administration. Application of Drugs to skin wounds or to skin with impaired barrier function may pose a risk factor for its occurrence. TEN or SJS following non-mucosal Topical Drug application seems to be extremely rare.
Ilva D. Rupenthal - One of the best experts on this subject based on the ideXlab platform.
-
In vitro and ex vivo corneal penetration and absorption models
Drug Delivery and Translational Research, 2016Co-Authors: Priyanka Agarwal, Ilva D. RupenthalAbstract:Topical Drug Administration is the preferred route of Drug delivery to the eye despite the poor bioavailability. To develop more efficient Drug carriers, reliable in vitro or ex vivo models are required in the early stages of formulation development, with such methods being faster, cheaper, and more ethical alternatives to in vivo studies. In vitro cell culture models are increasingly being used for transcorneal penetration studies, with primary cell cultures and immortalized cell lines now giving way to the development of organotypic corneal constructs for studying ocular Drug bioavailability. Artificially cultured human corneal equivalents are still in the early stages of development, but present tremendous potential for corneal penetration studies. Ex vivo models using excised animal tissue are also being used to study corneal penetration with promising results, although significant inter-species variations need to be considered. This review discusses the in vitro and ex vivo models currently being used to study corneal penetration and evaluates their advantages and limitations with a focus on diffusion cell assemblies. In addition to the tissue used, the diffusion cell set-up can significantly influence the penetration profile and should be cautiously adjusted to simulate clinical conditions.
Jessica M. Meekins - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of systemic absorption and renal effects of Topical ophthalmic flurbiprofen and diclofenac in healthy cats
Veterinary ophthalmology, 2016Co-Authors: Rick Lanuza, Amy J. Rankin, Butch Kukanich, Jessica M. MeekinsAbstract:OBJECTIVE To investigate systemic absorption and renal effects of Topically applied ophthalmic flurbiprofen and diclofenac in healthy cats. ANIMALS STUDIED Twelve domestic shorthair cats. PROCEDURES Cats were randomly assigned to two treatment groups (n = 6) and administered one drop (approximately 40 μL) of either flurbiprofen 0.03% or diclofenac 0.1% in both eyes four times daily (6 am, 12 pm, 6 pm, and 12 am) for 14 days. Blood samples were collected on days 0, 4, 8, 14, 16, and 17 and analyzed by liquid chromatography and mass spectrometry for flurbiprofen and diclofenac plasma concentrations. A complete blood count (CBC), serum chemistry, and urinalysis were analyzed at the beginning of the study (Day 0) and at the end of Topical Drug Administration (Day 15). RESULTS Both Drugs demonstrated systemic absorption. Flurbiprofen was detected (mean ± SD) at day 4 (237 ± 65 ng/mL), day 8 (396 ± 91 ng/mL), day 14 (423 ± 56 ng/mL), day 16 (350 ± 66 ng/mL), and day 17 (270 ± 62 ng/mL), and diclofenac was detected (mean ± SD) at day 4 (130 ± 44 ng/mL), day 8 (131 ± 25 ng/mL), day 14 (150 ± 36 ng/mL), and sporadically on day 16 [corrected]. Flurbiprofen plasma concentration decreased slowly over 48 h after the last dose. No clinically significant abnormalities were noted in the serum blood urea nitrogen, creatinine, or urine specific gravity at the end of Topical Drug Administration compared to the beginning of the study. CONCLUSIONS Flurbiprofen and diclofenac were systemically absorbed after Topical Administration four times daily to both eyes of healthy cats. Flurbiprofen reached higher plasma concentrations compared to diclofenac.
-
Evaluation of systemic absorption and renal effects of Topical ophthalmic flurbiprofen and diclofenac in healthy cats.
Veterinary ophthalmology, 2015Co-Authors: Rick Lanuza, Amy J. Rankin, Butch Kukanich, Jessica M. MeekinsAbstract:To investigate systemic absorption and renal effects of Topically applied ophthalmic flurbiprofen and diclofenac in healthy cats. Twelve domestic shorthair cats. Cats were randomly assigned to two treatment groups (n = 6) and administered one drop (approximately 40 μL) of either flurbiprofen 0.03% or diclofenac 0.1% in both eyes four times daily (6 am, 12 pm, 6 pm, and 12 am) for 14 days. Blood samples were collected on days 0, 4, 8, 14, 16, and 17 and analyzed by liquid chromatography and mass spectrometry for flurbiprofen and diclofenac plasma concentrations. A complete blood count (CBC), serum chemistry, and urinalysis were analyzed at the beginning of the study (Day 0) and at the end of Topical Drug Administration (Day 15). Both Drugs demonstrated systemic absorption. Flurbiprofen was detected (mean ± SD) at day 4 (237 ± 65 ng/mL), day 8 (396 ± 91 ng/mL), day 14 (423 ± 56 ng/mL), day 16 (350 ± 66 ng/mL), and day 17 (270 ± 62 ng/mL), and diclofenac was detected (mean ± SD) at day 4 (130 ± 44 ng/mL), day 8 (131 ± 25 ng/mL), day 14 (150 ± 36 ng/mL), and sporadically on day 16 [corrected]. Flurbiprofen plasma concentration decreased slowly over 48 h after the last dose. No clinically significant abnormalities were noted in the serum blood urea nitrogen, creatinine, or urine specific gravity at the end of Topical Drug Administration compared to the beginning of the study. Flurbiprofen and diclofenac were systemically absorbed after Topical Administration four times daily to both eyes of healthy cats. Flurbiprofen reached higher plasma concentrations compared to diclofenac. © 2015 American College of Veterinary Ophthalmologists.
Hirak K. Patra - One of the best experts on this subject based on the ideXlab platform.
-
Progress and perspective of microneedle system for anti-cancer Drug delivery.
Biomaterials, 2020Co-Authors: Hirak K. Patra, Xiangrui Liu, Zhuxian Zhou, Jianbin Tang, Nigel K.h. Slater, Youqing ShenAbstract:Abstract Transdermal Drug delivery exhibited encouraging prospects, especially through superficial Drug Administration routes. However, only a few limited lipophilic Drug molecules could cross the skin barrier, those are with low molecular weight and rational Log P value. Microneedles (MNs) can overcome these limitations to deliver numerous Drugs into the dermal layer by piercing the outermost skin layer of the body. In the case of superficial cancer treatments, Topical Drug Administration faces severely low transfer efficiency, and systemic treatments are always associated with side effects and premature Drug degradation. MN-based systems have achieved excellent technical capabilities and been tested for pre-clinical chemotherapy, photothermal therapy, photodynamic therapy, and immunotherapy. In this review, we will focus on the features, progress, and opportunities of MNs in the anticancer Drug delivery system. Then, we will discuss the strategies and advantages in these works and summarize challenges, perspectives, and translational potential for future applications.